FRIDAY, Jan. 29, 2021 (HealthDay Information)
Individuals spend virtually three instances a lot more for prescription medication than individuals in dozens of other international locations, a new study demonstrates.
Scientists analyzed 2018 details and uncovered that prescription drug price ranges in the United States average 2.5 times a lot more than in 32 other Firm for Financial Co-procedure and Progress (OECD) nations.
The price tag of model-identify medications is even additional — an common of 3.4 instances better — in the United States than in other countries.
On the other hand, generic medicines are marginally less expensive in the United States than in most other nations. In this nation, generic medication account for 84% of medicines sold by volume but only 12% of drug expending, in accordance to the researchers at the RAND Corp., a nonprofit, nonpartisan investigate group.
“Manufacturer-identify medicines are the key driver of the larger prescription drug rates in the U.S.,” claimed review creator Andrew Mulcahy, a senior health policy researcher at RAND. “We identified constantly high U.S. model-identify price ranges, no matter of our methodological choices.”
For their study, the researchers used producer selling prices for medication owing to a lack of availability of web charges, which are all those eventually paid out for medications after negotiated rebates and other bargains are applied.
But even soon after altering U.S. charges downward based mostly on believed discount rates, U.S. drug charges remained substantially greater than those in other countries.
Between other nations, the United Kingdom, France and Italy normally have the least expensive prescription drug price ranges, even though Canada, Germany and Japan tend to have increased costs, according to the review, which is obtainable on the RAND web-site and the U.S. Section of Overall health and Human Solutions web-site.
“Many of the most costly drugs are the biologic treatment plans that we normally see marketed on tv,” Mulcahy mentioned in a RAND information launch. “The hope is that competition from biosimilars will drive down selling prices and shelling out for biologics. But biosimilars are out there for only a handful of biologics in the United States.”
Across all the nations in the analyze, complete drug investing in 2018 was an estimated $795 billion. The United States accounted for 58% of product sales, but just 24% of the quantity.
U.S. drug shelling out surged 76% among 2000 and 2017, and is expected to improve quicker than other spots of health care paying about the following 10 years as new, costly specialty medications are permitted, according to RAND.
Far more information
The American Clinical Association has much more on prescription drug costs.
Source: RAND Corp., news release, Jan. 28, 2021
Copyright © 2020 HealthDay. All rights reserved.